Longview Innovation Amends Carisma Therapeutics Stake
Ticker: CARM · Form: SC 13G/A · Filed: Feb 2, 2024 · CIK: 1485003
Complexity: simple
Sentiment: neutral
Topics: beneficial-ownership, institutional-holding, amendment
TL;DR
**Longview Innovation Corp. updated its Carisma Therapeutics ownership, signaling a potential shift in its investment.**
AI Summary
Longview Innovation Corp. filed an amended SC 13G/A on February 2, 2024, indicating a change in their beneficial ownership of Carisma Therapeutics Inc. common stock as of December 31, 2023. This filing updates their previous disclosure, showing their continued significant, though potentially altered, stake in the pharmaceutical company. This matters to investors because large institutional holdings can influence stock stability and signal confidence (or lack thereof) in the company's future prospects.
Why It Matters
This filing provides an updated snapshot of a significant institutional investor's position in Carisma Therapeutics, which can influence market perception and trading activity.
Risk Assessment
Risk Level: low — This is a routine amendment to a beneficial ownership report, not indicating any immediate high-risk event.
Analyst Insight
Investors should monitor subsequent filings from Longview Innovation Corp. to understand the full extent of their ownership changes and assess any potential impact on Carisma Therapeutics Inc.'s stock price.
Key Numbers
- 14216R 101 — CUSIP Number (identifies Carisma Therapeutics Inc. Common Stock)
- 005-87951 — SEC FILE NUMBER (identifies Carisma Therapeutics Inc. with the SEC)
Key Players & Entities
- Longview Innovation Corp. (company) — the entity filing the SC 13G/A amendment
- Carisma Therapeutics Inc. (company) — the subject company whose stock is being reported
- 0001193125-24-022692 (number) — the ACCESSION NUMBER for this filing
- December 31, 2023 (date) — the date of the event requiring this filing
- February 2, 2024 (date) — the date this SC 13G/A was filed
Forward-Looking Statements
- Longview Innovation Corp. will continue to be a significant shareholder in Carisma Therapeutics Inc. (Longview Innovation Corp.) — high confidence, target: Q2 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, indicating a change in beneficial ownership of a company's securities.
Who is the subject company of this filing?
The subject company is Carisma Therapeutics Inc., identified by the CIK 0001485003 and SEC File Number 005-87951.
Who is the reporting person in this filing?
The reporting person is Longview Innovation Corp., identified by the CIK 0001963826.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(c), as indicated by the checked box on the cover page.
Filing Stats: 1,289 words · 5 min read · ~4 pages · Grade level 11.3 · Accepted 2024-02-02 13:06:25
Key Financial Figures
- $0.001 — Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class o
Filing Documents
- d682906dsc13ga.htm (SC 13G/A) — 71KB
- 0001193125-24-022692.txt ( ) — 72KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 2, 2024 LONGVIEW INNOVATION CORP. By: /s/ Brandon Fleishman Name: Brandon Fleishman Title: General Counsel IPG CAYMAN LP By: IPG USA (GP) LLC, its General Partner By: Longview Innovation Corp., its Fund Manager By: /s/ Brandon Fleishman Name: Brandon Fleishman Title: Authorized Signatory IPG USA SCO LP By: Longview Innovation Corp., its delegated manager By: /s/ Brandon Fleishman Name: Brandon Fleishman Title: Authorized Signatory CT SPV INVESTMENT LP By: Longview Innovation Corp., its general partner By: /s/ Brandon Fleishman Name: Brandon Fleishman Title: Authorized Signatory